ReviewJournal of inflammation research2026
Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is a chronic inflammatory bowel disease requiring long-term therapeutic strategies that balance efficacy, safety and durability/ persistence. As treatment targets have evolved toward deep remission, including clinical, endoscopic and histologic healing, there remains un unmet need for therapies that provide sustained benefit with selective immunomodulation. Interleukin-23 (IL-23) plays a central role in Th17-mediated mucosal inflammation, making selective IL-23p19 inhibition an attractive approach. Guselkumab, a fully human monoclonal antibody targeting IL-23p19, has demonstrated consistent efficacy and a favorable safety profile in Phase II and III clinical trials for moderate-to-severe UC. Data from the QUASAR and ASTRO programs show significant improvements in clinical, endoscopic, histologic and various quality of life (eg fatigue, urgency) outcomes during both induction and maintenance, with durable responses, corticosteroid-sparing effects, and efficacy across biologic-naïve and biologic-experienced populations. Emerging evidence also suggests a potential role of guselkumab within advanced combination strategies, although this approach remains investigational. This review summarizes the mechanistic rationale, pivotal clinical evidence, and practical considerations informing the positioning of guselkumab within contemporary UC treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.